New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
14:54 EDTDEPO, PDLIPDL BioPharma says concluding talks with SEC on Depomed deal accounting
PDL BioPharma (PDLI) disclosed in a regulatory filing that the company is currently concluding discussions with the SEC staff after receiving a comment letter to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, that requested additional information about the company’s accounting for the royalty purchase and sale agreement with Depomed (DEPO). "The Company’s responses to those comments may affect the narrative disclosures and financial statements included in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2014. All of the comments cannot be resolved by the prescribed due date for the Current Quarterly Report without unreasonable effort or expense," PDL stated. The company intends to file its current quarterly report by not later than Monday, August 18, PDL added.
News For PDLI;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:09 EDTPDLIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
07:37 EDTDEPOStifel to hold a conference
Subscribe for More Information
November 14, 2014
07:02 EDTPDLIPDL BioPharma announces conclusion of revenue interest agreement with AxoGen
PDL BioPharma (PDLI) announced that the company has received $30.3M, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen (AXGN). In October 2012, PDL entered into a structured financing transaction in which PDL provided AxoGen with an aggregate of $20.8M in exchange for royalties on certain AxoGen revenues.
November 10, 2014
16:11 EDTPDLIPDL BioPharma reports Q3 EPS 61c, consensus 56c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use